Abstract
Many studies have shown that patients infected with hepatitis C virus (HCV) of genotype 2 have better response to interferon (IFN)-α treatment than genotype 1 patients; however, the mechanisms responsible for this difference are not understood. In this study, viral dynamics during high-dose IFN induction treatment were compared between the genotypes. Patients in each group received 10 MU of IFN-α2b for 14 days, and HCV RNA levels were frequently determined. Nonlinear fitting, both individually for each patient and using a mixed-effects approach, of the viral kinetic data to a mathematical model of the IFN effect on HCV infection was performed. The antiviral effectiveness of IFN in blocking virus production, the free virion clearance rate, and the HCV-infected cell death rate were all significantly higher for genotype 2 patients than for genotype 1 patients. Thus, the better response rate of patients infected with HCV genotype 2 is multifactorial. This is the first finding of a difference in viral dynamics between subtypes of the same virus and demonstrates the importance of subtype-specific virushost-drug interactions.
| Original language | English |
|---|---|
| Pages (from-to) | 28-35 |
| Number of pages | 8 |
| Journal | Journal of Infectious Diseases |
| Volume | 182 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2000 |
Bibliographical note
Funding Information:Financial support: Gonda-Goldschmied Medical Diagnostic Center and the Committee for the Advancement of Research of Bar-Ilan University; Santa Fe Institute; Schering Plough Corporation, Kenilworth, NJ; Joseph P. Sullivan and Jeanne M. Sullivan Foundation; and National Institutes of Health (grants RR06555, A1/DK41320-2, and A139049-2).
Funding
Financial support: Gonda-Goldschmied Medical Diagnostic Center and the Committee for the Advancement of Research of Bar-Ilan University; Santa Fe Institute; Schering Plough Corporation, Kenilworth, NJ; Joseph P. Sullivan and Jeanne M. Sullivan Foundation; and National Institutes of Health (grants RR06555, A1/DK41320-2, and A139049-2).
| Funders | Funder number |
|---|---|
| Committee for the Advancement of Research of Bar-Ilan University | |
| Gonda-Goldschmied Medical Diagnostic Center | |
| Schering Plough Corporation | |
| National Institutes of Health | RR06555, A1/DK41320-2, A139049-2 |
| National Institute of Allergy and Infectious Diseases | R29AI039049 |
| Santa Fe Institute |